LCAM
ACTU

Long Corridor Asset Management’s Actuate Therapeutics ACTU Stock Holding History

Long Corridor Asset Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-125,000
Closed -$931K – 24
2024
Q3 		$931K Buy
+125,000
New +$990K 0.82% 15

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NU
Northwestern University Evanston, Illinois $63.3M AUM 0.76% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLCM
KG&L Capital Management Saint Francisville, Louisiana $139M AUM 26.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Long Corridor Asset Management's ACTU Position: Q4 2024 in Review

Long Corridor Asset Management sold out of Actuate Therapeutics (ACTU) in Q4 2024, closing a stake of 125,000 shares — an estimated $931K sold.

Long Corridor Asset Management first reported a position in ACTU in Q3 2024 and held it in 1 quarter. The position peaked at $931K in Q3 2024. 19 funds tracked by Wall St. Rank hold ACTU as of Q4 2024.

  • Long Corridor Asset Management reported no remaining Actuate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Long Corridor Asset Management sold 125,000 Actuate Therapeutics shares in Q4 2024, an estimated $931K.
  • Long Corridor Asset Management first reported a position in Actuate Therapeutics in Q3 2024 and held it in 1 quarter.
  • Long Corridor Asset Management's Actuate Therapeutics position peaked at $931K in Q3 2024.
  • 19 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q4 2024.

Based on Long Corridor Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.